We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+33.77%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.6B
AUM Growth
+$3.41B
Cap. Flow
-$91.9M
Cap. Flow %
-0.59%
Top 10 Hldgs %
85.51%
Holding
100
New
7
Increased
16
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$48.4M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$32.3M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$30.8M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$23.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$11.1M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$115M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$46.5M
3
ARRY
Array Biopharma Inc
ARRY
+$25M
4
SLDB icon
Solid Biosciences
SLDB
+$15.8M
5
NVAX icon
Novavax
NVAX
+$8.68M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IFRX icon
51
InflaRx
IFRX
$245M
$6.76M 0.04%
178,987
– –
FSTX
52
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$6.43M 0.04%
153,286
– –
BLUE
53
DELISTED
bluebird bio
BLUE
$6.29M 0.04%
3,088
– –
APLS
54
DELISTED
Apellis Pharmaceuticals
APLS
$6.12M 0.04%
313,725
+117,647
+60% +$1.85M
VYNE icon
55
VYNE Therapeutics
VYNE
$5.5M 0.04%
194
– –
MGNX icon
56
MacroGenics
MGNX
$234M
$5.44M 0.03%
+302,600
New +$5.23M
SYRS
57
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.25M 0.03%
57,484
– –
PTGX icon
58
Protagonist Therapeutics
PTGX
$8.73B
$5.08M 0.03%
+403,893
New +$3.57M
AUTL
59
Autolus Therapeutics
AUTL
$381M
$4.93M 0.03%
156,773
– –
HALO icon
60
Halozyme
HALO
$9.87B
$4.83M 0.03%
299,969
– –
VKTX icon
61
Viking Therapeutics
VKTX
$3.87B
$4.22M 0.03%
425,000
– –
FTSV
62
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$4.04M 0.03%
250,000
– –
XLRN
63
DELISTED
Acceleron Pharma
XLRN
$3.91M 0.03%
83,900
– –
ACOR
64
DELISTED
Acorda Therapeutics
ACOR
$3.88M 0.02%
+2,434
New +$4.38M
SRRA
65
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.42M 0.02%
50,000
– –
LJPC
66
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.25M 0.02%
505,240
+350,565
+227% +$2.28M
ACHN
67
DELISTED
Achillion Pharmaceuticals
ACHN
$3.24M 0.02%
1,095,359
– –
ARAV
68
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.03M 0.02%
430,885
+26,501
+7% +$138K
CRNX icon
69
Crinetics Pharmaceuticals
CRNX
$8.88B
$2.99M 0.02%
131,250
– –
LKFT
70
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$2.95M 0.02%
25,072
– –
ASMB icon
71
Assembly Biosciences
ASMB
$495M
$2.93M 0.02%
12,382
– –
CCXI
72
DELISTED
ChemoCentryx, Inc.
CCXI
$2.88M 0.02%
207,029
– –
YMAB
73
DELISTED
Y-mAbs Therapeutics
YMAB
$2.69M 0.02%
102,800
– –
ALKS icon
74
Alkermes
ALKS
$8.14B
$2.44M 0.02%
67,000
– –
ORTX
75
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$2.23M 0.01%
12,500
– –
1 2
3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2019 Portfolio in Review

As of Q1 2019, Baker Bros. Advisors held 100 positions worth $15.6B, up 28% from $12.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q1 2019 filing shows 7 new, 16 increased, 6 reduced and 4 closed positions. Its largest new stake was Axsome Therapeutics: 1,200,000 shares worth $17.1M. The largest sale was Genomic Health, Inc., an estimated $115M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q1 2019 buy was Axsome Therapeutics: 1,200,000 shares worth $17.1M.
  • Baker Bros. Advisors added most to Ascendis Pharma A/S in Q1 2019, an estimated $48.4M increase.
  • Baker Bros. Advisors's biggest Q1 2019 reduction was Genomic Health, Inc., cutting an estimated $115M.
  • Baker Bros. Advisors fully exited Solid Biosciences in Q1 2019, selling an estimated $15.8M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $15.6B portfolio in Q1 2019.
  • Baker Bros. Advisors opened 7 new positions and closed 4 in Q1 2019.
  • Baker Bros. Advisors's portfolio value rose 28% quarter-over-quarter to $15.6B.

Based on Baker Bros. Advisors's 13F filing for Q1 2019, filed 15 May 2019.